{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062036","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.350837+00:00","generated_at":"2026-06-08T07:14:24.039361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVITA Medical Q3 commercial revenue up 51% to $13.5M; net loss $8.7M","bullets":["Commercial revenue $13.5M (+51% YoY); total revenue $13.6M; gross margin 84.5%.","Net loss $8.7M ($0.34 loss per share) vs $5.6M loss a year ago; operating expenses $21.0M.","Q4 2023 revenue guidance $15.3M-$16.3M (64%-73% YoY growth); full-year $51M-$53M.","Secured up to $90M debt facility; $40M drawn at closing; cash $60.1M as of Sept 30.","Expect FDA approval of RECELL GO by May 30, 2024; targeting profitability in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062036","json":"https://secwatch.observer/filing/0000950170-23-062036.json","markdown":"https://secwatch.observer/filing/0000950170-23-062036.md","text":"https://secwatch.observer/filing/0000950170-23-062036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/0000950170-23-062036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/rcel-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:14:24.039361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"041776d032dc0444ce749758692bb5bd00f75134","claim":"AVITA Medical, Inc. reported the third quarter ended September 30, 2023 results: revenue $13.6 million, net income $8.7 million, EPS $0.34 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"$13.5 million in the three-months ended September 30, 2023, compared to $9.0 million in the same period in 2022. Total revenue, which includes BARDA revenue, increased by 50% to $13.6 million compared to $9.1 million in the same period in 2022. Gross profit margin increased by 1.3% to 84.5% compared to 83.2% for the third quarter of 2022. The increase was largely","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1762303/000095017023062036/0000950170-23-062036-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$13.6 million"},{"label":"Net income","value":"$8.7 million"},{"label":"EPS","value":"$0.34 per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}